扶正抗癌方联合吉非替尼治疗晚期肺腺癌疗效观察
|
摘要
目的:观察扶正抗癌方联合吉非替尼治疗晚期肺腺癌的临床效果。方法:选取90例晚期肺腺癌患者作为研究对象,按随机数字表法分为对照组和试验组,每组45例。对照组采用吉非替尼治疗;试验组在对照组基础上加用扶正抗癌方治疗,观察治疗后两组患者临床疗效、T淋巴细胞水平、生存质量和不良反应。结果:治疗后对照组有效率为64.44%,试验组有效率为80.00%,两组比较,差异有统计学意义(P<0.05);治疗后试验组患者CD_3~+、CD_4~+、CD_8~+水平高于对照组,CD_4~+/CD_8~+水平低于对照组,两组比较,差异有统计学意义(P<0.05);生存质量方面,两组患者角色功能、社会功能、情绪功能、躯体功能比较,差异有统计学意义(P<0.05);两组患者白细胞减少、皮疹瘙痒、肝肾功能损害、恶心呕吐、腹泻不良发生率比较,差异有统计学意义(P<0.05)。结论:扶正抗癌方联合吉非替尼治疗晚期肺腺癌患者临床效果显著,可改善患者T淋巴细胞水平及生存质量,减少不良反应。
Objective: To observe the clinical effects of Fuzheng Kang'ai Prescription and Gefitinib in treatment of advanced Lung adenocarcinoma in order to find the best treatment. Methods: Ninety patients with advanced lung adenocarcinoma were selected as study subjects and were randomly divided into two groups. 45 patients in the control group were treated with gefitinib and 45 patients in the experimental group were treated with Fuzheng Kangai Prescription in addition to that of the control group. The clinical efficacy,T lymphocyte levels,quality of life,and adverse reactions in both groups after treatment were observed. Results: After treatment,the effective rate in the control group was 64. 44%,and the effective rate in the experimental group was 80%. The difference between the two groups was statistically significant( P < 0. 05). The levels of CD_3~+,CD_4~+,and CD_8~+in the experimental group were significantly higher than those in the control group after treatment,and the level of CD_4~+/CD_8~+was significantly lower than that of the control group( P < 0. 05). There was a statistically significant difference in the quality of life between the two groups in terms of social role and function,emotional function and physical function( P < 0. 05). There was a statistically significant difference in the incidence of leukopenia,pruritus,liver and kidney dysfunction,nausea and vomiting,and diarrhea between the two groups( P < 0. 05). Conclusion: Fuzheng Kang'ai Prescription combined with gefitinib has significant clinical effect on patients with advanced Lung adenocarcinoma,which can improve the level of T lymphocytes and patients' quality of life as well as reducing the adverse reactions.
Objective: To observe the clinical effects of Fuzheng Kang'ai Prescription and Gefitinib in treatment of advanced Lung adenocarcinoma in order to find the best treatment. Methods: Ninety patients with advanced lung adenocarcinoma were selected as study subjects and were randomly divided into two groups. 45 patients in the control group were treated with gefitinib and 45 patients in the experimental group were treated with Fuzheng Kangai Prescription in addition to that of the control group. The clinical efficacy,T lymphocyte levels,quality of life,and adverse reactions in both groups after treatment were observed. Results: After treatment,the effective rate in the control group was 64. 44%,and the effective rate in the experimental group was 80%. The difference between the two groups was statistically significant( P < 0. 05). The levels of CD_3~+,CD_4~+,and CD_8~+in the experimental group were significantly higher than those in the control group after treatment,and the level of CD_4~+/CD_8~+was significantly lower than that of the control group( P < 0. 05). There was a statistically significant difference in the quality of life between the two groups in terms of social role and function,emotional function and physical function( P < 0. 05). There was a statistically significant difference in the incidence of leukopenia,pruritus,liver and kidney dysfunction,nausea and vomiting,and diarrhea between the two groups( P < 0. 05). Conclusion: Fuzheng Kang'ai Prescription combined with gefitinib has significant clinical effect on patients with advanced Lung adenocarcinoma,which can improve the level of T lymphocytes and patients' quality of life as well as reducing the adverse reactions.
引文
[1]陈晓,刘良,周华,等.扶正抗癌方联合吉非替尼治疗晚期非小细胞肺癌患者血浆差异蛋白比较分析[J].现代中西医结合杂志,2013,22(14):1487-1490.
[2]吴万垠,欧阳育树,廖桂雅,等.扶正抗癌方联合吉非替尼治疗难治性晚期非小细胞肺癌[C].北京:2013年全国中医肿瘤学术年会论文集,2013:107-113.
[3]柴小姝,吴万垠,李柳宁,等.扶正抗癌方联合吉非替尼治疗PS≤2分晚期NSCLC的疗效与安全性研究[J].现代中西医结合杂志,2014,23(3):229-231,250.
[4]陈世敏,廖桂雅,吴万垠,等.扶正抗癌方对吉非替尼作用于A549人肺癌细胞的增敏作用与机制[C].北京:2013年全国中医肿瘤学术年会论文集,2013:333-340.
[5]吴万垠,杨小兵,龙顺钦,等.抗癌扶正方联合吉非替尼治疗男性吸烟晚期非小细胞肺癌[C].北京:首届全国中医肿瘤高峰论坛论文集,2012:97-101.
[6]段昕,贾春芳,段敏,等.扶正抗癌方联合化疗治疗中晚期非小细胞肺癌疗效观察[J].陕西中医,2014,35(3):311,347.
[7]何敏,周浴,邝军,等.扶正抗癌方联合化疗治疗非小细胞肺癌疗效研究[J].环球中医药,2014,7(4):278-281.
[8]陆清昀.扶正抗癌方对大肠癌肿瘤患者免疫功能的影响[J].浙江中医药大学学报,2012,34(5):688-689.
[9]胡定政.扶正抗癌方对60例晚期非小细胞肺癌放、化疗的增效解毒临床观察[J].陕西中医,2012,26(3):209-211.
[10]杨洋,杨得振.中西医结合治疗中晚期非小细胞肺癌[J].现代中西医结合杂志,2011,20(12):1445-1446,1491.
[11]徐彬,李智强,王小龙,等.扶正抗癌方对化疗患者毒副反应的影响[J].河北中医,2013,35(8):1137-1138,1275.
[12]邹景宇.三黄三仙汤防治晚期肺癌化疗患者白细胞减少症临床研究[J].中医学报,2015,30(3):325-327.
[13]靳冬民.自拟肺癌方治疗晚期肺癌临床研究[J].中医学报,2013,28(10):1440-1442.
[14]侯丽,张雅月,刘伟,等.中西医结合对晚期肺癌患者生活质量及免疫功能的影响[J].中医学报,2013,28(6):779-781.
[15]李文明,李忠.中医药治疗中晚期肺癌临床研究[J].中医学报,2014,29(4):470-472,475.
[2]吴万垠,欧阳育树,廖桂雅,等.扶正抗癌方联合吉非替尼治疗难治性晚期非小细胞肺癌[C].北京:2013年全国中医肿瘤学术年会论文集,2013:107-113.
[3]柴小姝,吴万垠,李柳宁,等.扶正抗癌方联合吉非替尼治疗PS≤2分晚期NSCLC的疗效与安全性研究[J].现代中西医结合杂志,2014,23(3):229-231,250.
[4]陈世敏,廖桂雅,吴万垠,等.扶正抗癌方对吉非替尼作用于A549人肺癌细胞的增敏作用与机制[C].北京:2013年全国中医肿瘤学术年会论文集,2013:333-340.
[5]吴万垠,杨小兵,龙顺钦,等.抗癌扶正方联合吉非替尼治疗男性吸烟晚期非小细胞肺癌[C].北京:首届全国中医肿瘤高峰论坛论文集,2012:97-101.
[6]段昕,贾春芳,段敏,等.扶正抗癌方联合化疗治疗中晚期非小细胞肺癌疗效观察[J].陕西中医,2014,35(3):311,347.
[7]何敏,周浴,邝军,等.扶正抗癌方联合化疗治疗非小细胞肺癌疗效研究[J].环球中医药,2014,7(4):278-281.
[8]陆清昀.扶正抗癌方对大肠癌肿瘤患者免疫功能的影响[J].浙江中医药大学学报,2012,34(5):688-689.
[9]胡定政.扶正抗癌方对60例晚期非小细胞肺癌放、化疗的增效解毒临床观察[J].陕西中医,2012,26(3):209-211.
[10]杨洋,杨得振.中西医结合治疗中晚期非小细胞肺癌[J].现代中西医结合杂志,2011,20(12):1445-1446,1491.
[11]徐彬,李智强,王小龙,等.扶正抗癌方对化疗患者毒副反应的影响[J].河北中医,2013,35(8):1137-1138,1275.
[12]邹景宇.三黄三仙汤防治晚期肺癌化疗患者白细胞减少症临床研究[J].中医学报,2015,30(3):325-327.
[13]靳冬民.自拟肺癌方治疗晚期肺癌临床研究[J].中医学报,2013,28(10):1440-1442.
[14]侯丽,张雅月,刘伟,等.中西医结合对晚期肺癌患者生活质量及免疫功能的影响[J].中医学报,2013,28(6):779-781.
[15]李文明,李忠.中医药治疗中晚期肺癌临床研究[J].中医学报,2014,29(4):470-472,475.